Compounds and methods for kinase modulation, and indications therefor

A method for treating a subject with a disease or condition selected from the group consisting of rheumatoid arthritis, osteoarthritis, osteoporosis, peri-prosthetic osteolysis, systemic sclerosis, demyelinating disorders, multiple sclerosis, Charcot Marie Tooth syndrome, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, global ischemia, ulcerative colitis, Crohn's disease, immune thrombocytopenic purpura, atherosclerosis, systemic lupus erythematosis, myelopreparation for autologous transplantation, transplant rejection, glomerulonephritis, interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic nephropathy, renal hypertrophy, type I diabetes, chronic pain, acute pain, inflammatory pain, neuropathic pain, bone pain, pain associated with cancer, surgery, or bone fracture, acute myeloid leukemia, melanoma, multiple myeloma, breast cancer, prostate cancer, pancreatic cancer, non-small cell lung cancer, ovarian cancer, gliomas, glioblastomas, neurofibromatosis, osteolytic bone metastases, brain metastases, gastrointestinal stromal tumors, and giant cell tumors, said method comprising administering to the subject in need thereof an effective amount of a compound of Formula Ia:

• or a salt thereof,
• wherein:
• Y2 is —N═ and R15 is hydrogen;
• or Y2 is —C(H)═ and R15 is fluoro or chloro;
• L2 is —CH2— or —C(O)—;
• Cy2 is cycloalkyl optionally substituted with one or more R16;
• R14 is —N(R9a)(R9b);
• R9a is H and R9b is selected from the group consisting of (i) H, lower alkyl, lower alkyl substituted with one or more substituents independently selected from fluoro, lower alkyl substituted with lower alkoxy, and lower alkyl substituted with hydroxyl, and (ii) cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, arylalkyl, or heteroarylalkyl, each of which is optionally substituted with one to three members independently selected from lower alkyl, haloalkyl, lower alkoxy, and fluoro;
• or
• R9a and R9b together with the nitrogen to which they are attached form a 5- or 6-membered ring having from 0 to 1 additional heteroatom selected from O, N, or S, each of which is optionally substituted with one to three members independently selected from lower alkyl, haloalkyl, lower alkoxy, and fluoro;
• and
• each R16 is independently selected from the group consisting of fluoro, —OH, lower alkyl optionally substituted with one or more substituents independently selected from fluoro, and lower alkoxy optionally substituted with one or more fluoro.